Latest News

Kamada announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention.

Sep. 5, 2018

Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation.

Kamada Provides Updated Full-Year 2018 Revenue Guidance

Aug. 29, 2018

As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year.

Upcoming Events

Kamada to present at the Cantor 2018 Global Healthcare Conference

Oct. 1-3, 2018 / New York, New York

The conference is a three-day multitrack event, which will feature over 200 innovative industry leaders from public and private companies for an in-depth discussion of the developments and trends shaping biotechnology, specialty pharmaceuticals, medical technology, healthcare facilities and services, and life sciences tools and diagnostics.

Kamada's CEO, Amir London,  will  present on: Wed, Oct 3 at 4:35-5:05 PM in Track 6 - Rockefeller Suite.

Kamada to participate in The MicroCap Conference

Oct. 1-2, 2018 / New-York City, USA

The MicroCap Conference is an exclusive event dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors.

Kamada CEO ,Amir London, will present on October 2 at 14:00.

Past Event

Kamada to participate in ERS International Congress 2018

Sep. 15-19, 2018 / Paris, France

ERS congress is the largest meeting of respiratory professionals in the world, with an outstanding scientific and educational programme designed to address the needs of researchers, clinicians, general practitioners and allied health professionals alike.

Covering key topics in respiratory medicine from across the spectrum of disease areas including TB, lung cancer, chronic and acute respiratory failure, sleep breathing disorders, interstitial lung diseases, pneumonia, cystic fibrosis, COPD and asthma, amongst others, the congress programme is set to deliver the best advances in both science and education.

This years’ congress will specifically highlight the importance of environment in respiratory health and focus on the need to personalise medicine in the respiratory arena. Special attention will also be paid to our interactions with microorganisms in our environment as well as those that live in peace within our organism.